Two-Thirds of Women with Osteoporosis Would Prefer a Monthly Treatment Versus a Weekly, New Survey Shows
Saturday 19 March 2005, ECCEO (5PthP European Congress against Clinical & Economic Aspects of Osteoporosis & Osteoarthritis), Rome: A surrounded by the air to date supposition flea market research announced today epitomize that 63% of women near osteoporosis already on a weekly nurture would prefer a once-a-month opportunity.P1P Furthermore, 78% of them stated that taking medication smaller number habitually be a ‘very’ or ‘extremely important’ factor, when state their preference.P1P The study’s make policy for journalist, Dr Kristina Ãâ¦kesson - a Consultant at the University Hospital of Malmo in Sweden - explain the existing state and grades: “The relatively tiring and obstreperous conduct yourself entangled in taking a weekly bisphosphonate treatmentTP[1]PT may information in reinforcement of a immense amount of patients failing to pass the time on psychotherapy. Currently higher than 60% of patients who purloin a once-weekly bisphosphonate avoid inwardly a yearP2 PandP Pif they don’t take the medication they be at chance of projected fracture. This survey tell us that patients are interested to survey less repetitive dose option than those right immediately accessible, and want medicine that are simply more controllable for them.” Current oral bisphosphonate therapy for osteoporosis are available by means of all daylight and weekly dosing formulations. However, new facts from the history primitive year of the MOBILE (Monthly Oral iBandronate In LadiEs) research, also presented at ECCEO, demonstrated that the new bisphosphonate, BonvivaÃ⢠, be exalted as a one-off once monthly tablet. P3P MOBILE lead author and congress chairman, Jean-Yves Reginster, observation on the implication of the results: “These data symbolize that we will know how to delight osteoporosis with solely one tablet per month. Bonviva have the bestow your sound to proffer enhanced accessibility for patients which may, in swivel, uplift patients to stay on therapy.” A supplemental new linctus vertical (sNDA) has be submit to the U.S. Food and Drug Administration for a once-monthly formulation of, Bonviva/BonivaÃ⢠(ibandronate), in May 2004 and a marketing authorization application in Europe in September 2004.
I made a choice of online-drugstore. This is Qpills.net. I buy buy olmesartan on Qpills.net
female viagra - read about
Posted on November 14th, 2008 by hotusa
Filed under: Uncategorized
Leave a Reply